⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118935 | 1.00 | — | — | |
| SCHEMBL122846 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2247010 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL640249 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL4849693 | 0.98 | — | — | |
| SCHEMBL26624304 | 0.93 | — | — | |
| Acetone SCHEMBL27869773 | 0.89 | SLC6A1 (0.44) | — | |
| SCHEMBL91546 | 0.84 | — | — | |
| SCHEMBL492237 | 0.84 | — | — | |
| SCHEMBL321509 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4709714-A1 | SUBSTITUTED QUINOXALINES | Mirati Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4637749-A2 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4600243-A2 | NOVEL BICYCLIC HETEROCYCLYL COMPOUNDS AND USE THEREOF | Jeil Pharmaceutical Co., Ltd. (KR) | 2025-08-13 | — | — | EP | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025067227-A1 | PREPARATION METHOD FOR CBL-B REGULATOR, AND USE | 浙江华海药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7494992-B2 | Antiparasitic terpene alkaloids | PFIZER INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7425554-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7410971-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
| US-20070185101-A1 | Antiparasitic terpene alkaloids | PFIZER PRODUCTS INC | 2007-08-09 | — | — | US | disclosed |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1597264-A2 | ANTIPARASITIC TERPENE ALKALOIDS | Pfizer Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072086-A2 | ANTIPARASITIC TERPENE ALKALOIDS | PFIZER LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |